DGX — Quest Diagnostics Incorporated

Quest Diagnostics Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $2.9 billion, up 9.2% year-over-year, primarily driven by organic growth (9%).
• Adjusted Diluted EPS: $2.50, a 13% increase from $2.21 in Q1 2025.
• Operating Income: Reported at $399 million (13.8% of revenues), adjusted operating income at $447 million (15.4% of revenues).
• Volume Growth: Total requisitions increased by 10.9%, with organic volume growth at 10.8%. Excluding contributions from Fresenius Medical Care and Corewell Health, organic volume growth was 3.8%.
• Cash from Operations: $278 million, down from $314 million in the prior year due to timing of receipts and higher bonus payments.

2. Strategic Updates and Business Highlights

• Clinical Innovations: Strong performance in advanced diagnostics, particularly in brain health (Alzheimer's testing), cardiometabolic, and endocrine testing.
• Consumer Health Growth: Significant revenue growth from questhealth.com and partnerships with consumer health brands, with high customer repeat rates.
• Collaborations: Continued success with Corewell Health and Fresenius Medical Care, contributing to organic volume growth and revenue.
• AI and Automation: Increased deployment of AI in operations, enhancing productivity in customer service and lab processes.
• Project Nova: Ongoing investments in transforming order-to-cash processes, with expected implementation of initial solutions in fall 2027.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Revised to $11.78 billion - $11.9 billion, reflecting a growth rate of 6.8% to 7.8%.
• EPS Guidance: Reported EPS expected between $9.58 and $9.78; adjusted EPS between $10.63 and $10.83.
• Cash from Operations: Projected at approximately $1.75 billion for the year, with capital expenditures around $550 million.

4. Bad News, Challenges, or Points of Concern

• Revenue per Requisition: Declined by 1.3% year-over-year, although it increased by 2.5% when excluding the impact of Fresenius and Corewell.
• Weather Impact: Negative revenue impact of approximately $9 million year-over-year due to weather disruptions, although recovery was noted in March.
• Fuel Costs: Anticipated higher fuel costs ($7 million to $10 million impact) embedded in guidance, affecting operational expenses.
• Regulatory Risks: Potential impacts from the CMS CRUSH initiative and the upcoming PAMA survey, although management believes Quest is not significantly affected.

5. Notable Q&A Insights

• Organic Volume Dynamics: Strong growth attributed to advanced diagnostics and consumer health initiatives. Management expects continued growth in the second half of the year.
• Impact of ACA Subsidies: No significant impact observed in Q1 from the expiration of ACA subsidies, with a 30 basis point revenue impact still embedded in guidance.
• M&A Environment: Positive outlook on M&A opportunities, particularly in health system outreach, though no contributions from M&A are included in the current guidance.
• AI and Wearables: Management emphasized the potential for AI and consumer health technologies to enhance patient engagement and testing frequency, indicating a shift towards more proactive health management.

Overall, Quest Diagnostics reported a strong start to 2026, with solid revenue growth driven by innovation and strategic partnerships, while also acknowledging challenges related to pricing pressures and operational costs.